{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:32:07Z","timestamp":1789129927718,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"DOI":"10.1186\/s13065-026-01792-3","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:48:28Z","timestamp":1776696508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of dapagliflozin and eplerenone in bulk and synthetic mixture"],"prefix":"10.1186","volume":"20","author":[{"given":"Prexa","family":"Tandel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiralben","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"1792_CR1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","volume":"133","author":"CC Low Wang","year":"2016","unstructured":"Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus. Circulation. 2016;133:2459\u2013502. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.022194.","journal-title":"Circulation"},{"key":"1792_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"key":"1792_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"key":"1792_CR4","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"TM Maddox","year":"2022","unstructured":"Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. Circulation. 2022;145:e895\u20131032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","journal-title":"Circulation"},{"key":"1792_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"key":"1792_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"key":"1792_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","volume":"53","author":"S Kasichayanula","year":"2014","unstructured":"Kasichayanula S, Liu X, Zhang W, Pfister M, Lacreta F, Boulton DW. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin. Clin Pharmacokinet. 2014;53:17\u201327. https:\/\/doi.org\/10.1007\/s40262-013-0104-3.","journal-title":"Clin Pharmacokinet"},{"key":"1792_CR8","unstructured":"AstraZeneca Pharmaceuticals LP. Farxiga (dapagliflozin) prescribing information. Wilmington (DE); 2023."},{"key":"1792_CR9","unstructured":"National Center for Biotechnology Information. PubChem compound summary for CID 9887712, Dapagliflozin; CID 443872, Eplerenone. Bethesda (MD): National Library of Medicine (US). 2025. https:\/\/pubchem.ncbi.nlm.nih.gov. Accessed 5 Jul 2025."},{"key":"1792_CR10","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321. https:\/\/doi.org\/10.1056\/NEJMoa030207.","journal-title":"N Engl J Med"},{"key":"1792_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492.","journal-title":"N Engl J Med"},{"key":"1792_CR12","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","volume":"31","author":"CS Cook","year":"2003","unstructured":"Cook CS, Berry LM, Bible RH, Hribar JD, Liu NW. Pharmacokinetics and metabolism of eplerenone. Drug Metab Dispos. 2003;31:1448\u201355. https:\/\/doi.org\/10.1124\/dmd.31.11.1448.","journal-title":"Drug Metab Dispos"},{"key":"1792_CR13","unstructured":"Pfizer Labs. Inspra (eplerenone) prescribing information. New York (NY); 2023."},{"key":"1792_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/chromsci\/bmw178","volume":"55","author":"AK Singh","year":"2017","unstructured":"Singh AK, Kumar S, Kaur H. Stability-indicating RP-HPLC method for determination of dapagliflozin. J Chromatogr Sci. 2017;55:293\u2013301. https:\/\/doi.org\/10.1093\/chromsci\/bmw178.","journal-title":"J Chromatogr Sci"},{"key":"1792_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jpba.2016.07.015","volume":"130","author":"EA Abdelaleem","year":"2016","unstructured":"Abdelaleem EA, Abdelwahab NS, El-Tohamy MF. LC\u2013MS\/MS determination of dapagliflozin in human plasma. J Pharm Biomed Anal. 2016;130:127\u201336. https:\/\/doi.org\/10.1016\/j.jpba.2016.07.015.","journal-title":"J Pharm Biomed Anal"},{"key":"1792_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jpba.2004.06.028","volume":"36","author":"N Erk","year":"2004","unstructured":"Erk N. Quantitative analysis of eplerenone by HPLC. J Pharm Biomed Anal. 2004;36:189\u201395. https:\/\/doi.org\/10.1016\/j.jpba.2004.06.028.","journal-title":"J Pharm Biomed Anal"},{"key":"1792_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/bmc.1262","volume":"24","author":"BN Patel","year":"2010","unstructured":"Patel BN, Sharma N, Sanyal M, Shrivastav PS. LC\u2013MS\/MS determination of eplerenone in human plasma. Biomed Chromatogr. 2010;24:124\u201331. https:\/\/doi.org\/10.1002\/bmc.1262.","journal-title":"Biomed Chromatogr"},{"key":"1792_CR18","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Validation of analytical procedures Q2(R2). Geneva; 2023."},{"key":"1792_CR19","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Stability testing of new drug substances and drug products Q1A(R2). Geneva; 2003."},{"key":"1792_CR20","volume-title":"United States Pharmacopeia 32\u2013National Formulary 27 (USP 32\u2013NF 27)","author":"United States Pharmacopeial Convention","year":"2009","unstructured":"United States Pharmacopeial Convention. United States Pharmacopeia 32\u2013National Formulary 27 (USP 32\u2013NF 27). 2nd suppl ed. Rockville (MD): United States Pharmacopeial Convention; 2009. General chapter < 621 > Chromatography.","edition":"2"},{"key":"1792_CR21","first-page":"7","volume":"5","author":"R Panchumarthy","year":"2015","unstructured":"Panchumarthy R, Naga Navya C, Pravallika D, Navya Sri D. A review on step-by-step analytical method validation. IOSR J Pharm. 2015;5:7\u201319.","journal-title":"IOSR J Pharm"},{"key":"1792_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s13065-025-01620-0","volume":"19","author":"S Shah","year":"2025","unstructured":"Shah S, Kotadiya R. A novel RP-HPLC approach for simultaneous determination of dapagliflozin, linagliptin, and metformin in pharmaceutical formulations. BMC Chem. 2025;19:257. https:\/\/doi.org\/10.1186\/s13065-025-01620-0.","journal-title":"BMC Chem"},{"key":"1792_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13065-024-011774","volume":"18","author":"SF El-Malla","year":"2024","unstructured":"El-Malla SF, Mansour FR, Elbastawissy ABB, et al. Development of a stability indicating high-performance liquid chromatography method for determination of cenobamate: study of basic degradation kinetics. BMC Chem. 2024;18:177. https:\/\/doi.org\/10.1186\/s13065-024-011774.","journal-title":"BMC Chem"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-026-01792-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-026-01792-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-026-01792-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:29:48Z","timestamp":1780536588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13065-026-01792-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1792"],"URL":"https:\/\/doi.org\/10.1186\/s13065-026-01792-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8677881\/v1","asserted-by":"object"}]},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}